SURGERY PARTNERS INC (SGRY) Stock Fundamental Analysis
USA - NASDAQ:SGRY - US86881A1007 - Common Stock
22.455 USD
-0.31 (-1.34%)
Overall SGRY gets a fundamental rating of 3 out of 10. We evaluated SGRY against 101 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of SGRY while its profitability can be described as average. While showing a medium growth rate, SGRY is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year SGRY was profitable.
SGRY had a positive operating cash flow in the past year.
In the past 5 years SGRY always reported negative net income.
In the past 5 years SGRY always reported a positive cash flow from operatings.
1.2 Ratios
With a Return On Assets value of -2.27%, SGRY is not doing good in the industry: 60.40% of the companies in the same industry are doing better.
SGRY has a Return On Equity (-10.32%) which is comparable to the rest of the industry.
SGRY's Return On Invested Capital of 5.18% is in line compared to the rest of the industry. SGRY outperforms 58.42% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for SGRY is below the industry average of 9.34%.
The last Return On Invested Capital (5.18%) for SGRY is above the 3 year average (5.03%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.27% | ||
| ROE | -10.32% | ||
| ROIC | 5.18% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
1.3 Margins
SGRY has a better Operating Margin (14.96%) than 87.13% of its industry peers.
In the last couple of years the Operating Margin of SGRY has remained more or less at the same level.
SGRY has a Gross Margin (26.51%) which is in line with its industry peers.
SGRY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.96% | ||
| PM (TTM) | N/A | ||
| GM | 26.51% |
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
SGRY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, SGRY has more shares outstanding
Compared to 5 years ago, SGRY has more shares outstanding
Compared to 1 year ago, SGRY has a worse debt to assets ratio.
2.2 Solvency
SGRY has an Altman-Z score of 0.83. This is a bad value and indicates that SGRY is not financially healthy and even has some risk of bankruptcy.
SGRY's Altman-Z score of 0.83 is on the low side compared to the rest of the industry. SGRY is outperformed by 76.24% of its industry peers.
SGRY has a debt to FCF ratio of 20.39. This is a negative value and a sign of low solvency as SGRY would need 20.39 years to pay back of all of its debts.
With a Debt to FCF ratio value of 20.39, SGRY perfoms like the industry average, outperforming 40.59% of the companies in the same industry.
A Debt/Equity ratio of 1.98 is on the high side and indicates that SGRY has dependencies on debt financing.
SGRY's Debt to Equity ratio of 1.98 is on the low side compared to the rest of the industry. SGRY is outperformed by 74.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.98 | ||
| Debt/FCF | 20.39 | ||
| Altman-Z | 0.83 |
ROIC/WACC0.56
WACC9.18%
2.3 Liquidity
SGRY has a Current Ratio of 1.93. This is a normal value and indicates that SGRY is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Current ratio value of 1.93, SGRY is doing good in the industry, outperforming 73.27% of the companies in the same industry.
A Quick Ratio of 1.78 indicates that SGRY should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.78, SGRY is doing good in the industry, outperforming 66.34% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.78 |
3. Growth
3.1 Past
The earnings per share for SGRY have decreased strongly by -10.64% in the last year.
Looking at the last year, SGRY shows a quite strong growth in Revenue. The Revenue has grown by 12.05% in the last year.
Measured over the past years, SGRY shows a quite strong growth in Revenue. The Revenue has been growing by 11.20% on average per year.
EPS 1Y (TTM)-10.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.05%
Revenue 1Y (TTM)12.05%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%8.41%
3.2 Future
SGRY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.60% yearly.
SGRY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.15% yearly.
EPS Next Y-5.38%
EPS Next 2Y6.97%
EPS Next 3Y10.64%
EPS Next 5Y21.6%
Revenue Next Year8.95%
Revenue Next 2Y9.27%
Revenue Next 3Y9.2%
Revenue Next 5Y10.15%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SGRY is valuated quite expensively with a Price/Earnings ratio of 26.73.
Based on the Price/Earnings ratio, SGRY is valued a bit cheaper than 60.40% of the companies in the same industry.
SGRY is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.76, which is the current average of the S&P500 Index.
SGRY is valuated rather expensively with a Price/Forward Earnings ratio of 20.88.
Based on the Price/Forward Earnings ratio, SGRY is valued a bit cheaper than 60.40% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.63, SGRY is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.73 | ||
| Fwd PE | 20.88 |
4.2 Price Multiples
77.23% of the companies in the same industry are more expensive than SGRY, based on the Enterprise Value to EBITDA ratio.
SGRY's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. SGRY is cheaper than 74.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.42 | ||
| EV/EBITDA | 9.68 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.97%
EPS Next 3Y10.64%
5. Dividend
5.1 Amount
No dividends for SGRY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SGRY (10/30/2025, 10:50:57 AM)
22.455
-0.31 (-1.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners75.05%
Inst Owner Change0.05%
Ins Owners1.12%
Ins Owner Change-0.09%
Market Cap2.88B
Revenue(TTM)3.24B
Net Income(TTM)-180400000
Analysts81.11
Price Target31.82 (41.71%)
Short Float %18.56%
Short Ratio11.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.1%
Min EPS beat(2)-24.34%
Max EPS beat(2)24.15%
EPS beat(4)2
Avg EPS beat(4)-2.82%
Min EPS beat(4)-26.04%
Max EPS beat(4)24.15%
EPS beat(8)6
Avg EPS beat(8)7.1%
EPS beat(12)9
Avg EPS beat(12)175.54%
EPS beat(16)11
Avg EPS beat(16)112.22%
Revenue beat(2)0
Avg Revenue beat(2)-1.48%
Min Revenue beat(2)-2.1%
Max Revenue beat(2)-0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.62%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)2.34%
Revenue beat(8)3
Avg Revenue beat(8)-0.58%
Revenue beat(12)4
Avg Revenue beat(12)-0.9%
Revenue beat(16)6
Avg Revenue beat(16)-0.88%
PT rev (1m)0%
PT rev (3m)-2.05%
EPS NQ rev (1m)-2.16%
EPS NQ rev (3m)-29.19%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.95%
Revenue NQ rev (1m)-0.11%
Revenue NQ rev (3m)-1.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.73 | ||
| Fwd PE | 20.88 | ||
| P/S | 0.89 | ||
| P/FCF | 16.42 | ||
| P/OCF | 10.91 | ||
| P/B | 1.65 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.68 |
EPS(TTM)0.84
EY3.74%
EPS(NY)1.08
Fwd EY4.79%
FCF(TTM)1.37
FCFY6.09%
OCF(TTM)2.06
OCFY9.17%
SpS25.25
BVpS13.64
TBVpS-26.45
PEG (NY)N/A
PEG (5Y)N/A
Graham Number16.05
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.27% | ||
| ROE | -10.32% | ||
| ROCE | 6.56% | ||
| ROIC | 5.18% | ||
| ROICexc | 5.36% | ||
| ROICexgc | 19.21% | ||
| OM | 14.96% | ||
| PM (TTM) | N/A | ||
| GM | 26.51% | ||
| FCFM | 5.42% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
ROICexc(3y)5.23%
ROICexc(5y)4.72%
ROICexgc(3y)18.5%
ROICexgc(5y)17.9%
ROCE(3y)6.37%
ROCE(5y)5.69%
ROICexgc growth 3Y0.78%
ROICexgc growth 5Y0.88%
ROICexc growth 3Y4.99%
ROICexc growth 5Y3.37%
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
F-Score4
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.98 | ||
| Debt/FCF | 20.39 | ||
| Debt/EBITDA | 5.37 | ||
| Cap/Depr | 55.13% | ||
| Cap/Sales | 2.74% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 40.92% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.78 | ||
| Altman-Z | 0.83 |
F-Score4
WACC9.18%
ROIC/WACC0.56
Cap/Depr(3y)68.21%
Cap/Depr(5y)61.64%
Cap/Sales(3y)3.1%
Cap/Sales(5y)2.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.05%
EPS Next Y-5.38%
EPS Next 2Y6.97%
EPS Next 3Y10.64%
EPS Next 5Y21.6%
Revenue 1Y (TTM)12.05%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%8.41%
Revenue Next Year8.95%
Revenue Next 2Y9.27%
Revenue Next 3Y9.2%
Revenue Next 5Y10.15%
EBIT growth 1Y8.03%
EBIT growth 3Y15.97%
EBIT growth 5Y12.77%
EBIT Next Year49.11%
EBIT Next 3Y22.59%
EBIT Next 5YN/A
FCF growth 1Y138.83%
FCF growth 3Y92.28%
FCF growth 5Y30.27%
OCF growth 1Y61.41%
OCF growth 3Y51.04%
OCF growth 5Y18.3%
SURGERY PARTNERS INC / SGRY FAQ
Can you provide the ChartMill fundamental rating for SURGERY PARTNERS INC?
ChartMill assigns a fundamental rating of 3 / 10 to SGRY.
Can you provide the valuation status for SURGERY PARTNERS INC?
ChartMill assigns a valuation rating of 3 / 10 to SURGERY PARTNERS INC (SGRY). This can be considered as Overvalued.
How profitable is SURGERY PARTNERS INC (SGRY) stock?
SURGERY PARTNERS INC (SGRY) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for SGRY stock?
The Price/Earnings (PE) ratio for SURGERY PARTNERS INC (SGRY) is 26.73 and the Price/Book (PB) ratio is 1.65.
Is the dividend of SURGERY PARTNERS INC sustainable?
The dividend rating of SURGERY PARTNERS INC (SGRY) is 0 / 10 and the dividend payout ratio is 0%.